Ipsen S.A. publishes its 2023 Half-Year Financial Report

Regulated Information 19 September 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 37 – 2023

Regulated Information 12 September 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2023

Regulated Information 08 September 2023 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Regulated Information 05 September 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 35 – 2023

Corporate 04 September 2023 5 mins read

Ipsen nominates Pascal Touchon to its Board of Directors as new independent director

Corporate 01 September 2023 6 mins read

Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet

Regulated Information 29 August 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 34 – 2023

Regulated Information 22 August 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 33 – 2023

Corporate 16 August 2023 12 mins read

US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

Regulated Information 08 August 2023 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 31 – 2023